Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $13 price target.
September 24, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Charles Duncan has reiterated an Overweight rating for Marinus Pharma, maintaining a $13 price target. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $13 price target by a reputable analyst suggests a positive outlook for Marinus Pharma. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100